Isotype and affinity of anti-myeloperoxidase autoantibodies in systemic vasculitis  by Kokolina, Elisabeth et al.
Kidney International, Vol. 46 (1994), pp 177—1 84
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Isotype and affinity of anti.myeloperoxidase antibodies in systemic
vasculitis. The role of immunoglobulin (Ig) isotype and affinity of anti-
myeloperoxidase (MPO) antibodies in the clinical expression of vascu-
litis (organ involvement, severity and evolution) remains incompletely
defined. We have determined the anti-MPO antibody isotypes, as well
as the apparent affinity constant (aK) of anti-MPO IgG by using fluid
phase MPO inhibition of IgG binding in an MPO specific ELISA.
Twenty-eight patients with anti-MPO antibodies and necrotic and
crescentic glomerulonephritis, either isolated or associated to various
other organ localizations, were analyzed. Serum samples were obtained
before treatment and during follow-up. No association was observed
between the isotype, the level or apparent affinity of anti-MPO antibod-
ies and the clinical symptoms, severity, and organ distribution of
vasculitis, including alveolar hemorrhage. No significant correlation
was found between the apparent affinity and the level of anti-MPO IgG.
However, the presence of anti-MPO 1gM was clearly associated with
low affinity anti-MPO IgG and vice versa. Furthermore, in a longitudi-
nal study, high levels of anti-MPO 1gM, when present, were observed
early in the course of the disease and in some cases preceded the
reappearance of anti-MPO IgG during relapses. High affinity anti-MPO
IgG were usually present before treatment. Immunosuppressive ther-
apy resulted in decreased apparent affinity and level of anti-MPO IgG.
Importantly, anti-MPO IgG level increased during relapses but the
affinity of these IgG autoantibodies remained low. Thus, the analysis of
autoantibody affinity during treatment and relapses suggests that high
affinity anti-MPO IgG clones are suppressed after treatment for a
prolonged period of time and unexpectedly do not reappear during
relapses, as shown by the predominant recurrence of low affinity
anti-MPO IgGs.
Autoantibodies against myeloperoxidase (MPO) are antineu-
trophil cytoplasmic antibodies (ANCA) strongly associated
with systemic or isolated forms of vasculitis [1, 2, 3]. Today
ANCA are considered to be specific serological markers sup-
porting diagnosis, monitoring disease activity and assessing
therapeutic effectiveness [4, 5, 6]. In addition, there is evidence
that ANCA may be directly involved in the pathogenesis of
these diseases [7]. However, the exact role of ANCA in the
pathogenesis and the varied clinical manifestations of vasculitis
remains incompletely understood. High autoantibody titers are
usually observed at the onset of the disease and during relapses
but do not reflect the number of organs involved or the degree
of tissue injury [8, 9]. On the other hand, increasing ANCA
titers are not constantly followed by relapses, and in some
patients ANCA titers do not change over time despite clinical
quiescence [9, 10]. These observations suggest that in addition
to the level of anti-MPO antibodies, their isotype distribution or
affinity may be important factor(s) for clinical expression of the
disease. Indeed, the clinical relevance of the isotypic distribu-
tion of ANCA has been suggested by a previous work [11, 12].
This work showed such a strong association between pulmo-
nary hemorrhage and 1gM ANCA that these authors propose
special therapeutic consideration, namely plasmapheresis on
cytocentrifuge.
The rationale of our study was double: first, to assess if
anti-MPO ANCA affinity determination may have a clinical
interest with regard to organ distribution and severity of vas-
culitis and second, to reinvestigate the importance of 1gM
ANCA in our patients population. We studied sera from 28
patients with IgG MPO antibodies and determined the clinical
manifestations, the anti-MPO antibody isotypes and the affinity
of these autoantibodies at the onset of the disease and during
follow-up in 14 out of 28. Antibody affinity was determined
using fluid phase inhibition of the antibody binding to the MPO.
The apparent affinity constant (aK) was defined as the recipro-
cal value of molar concentrations of MPO in the liquid phase
resulting in 50% inhibition of the antibody binding to the MPO
in the solid phase, as previously described.
Our findings suggest that neither the affinity of anti-MPO IgG
nor the isotypic distribution of the anti-MPO antoantibodies are
associated with any particular clinical manifestations, severity
or organ distribution of vasculitis. During relapses, increasing
titers of anti-MPO 1gM sometimes preceded those of anti-MPO
IgG while high affinity anti-MPO IgG, regularly observed at
presentation, do not reappear.
Methods
Patients
Sera from 28 patients with circulating IgG anti-MPO ANCA
and biopsy-proven necrotic and crescentic glomerulonephritis
(NCGN), associated or not with extrarenal vasculitis, were
collected and studied. Among the 28 patients, six had Wegener
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granulomatosis (WG) defined by the presence of renal or
extrarenal granulomas on histological examination and/or the
destruction of the nasal wall, 18 had microscopic polyarteritis
(MPA) defined by NCGN associated with extrarenal vasculitis
involving small vessels, without granulomas or asthma [13],
three had isolated NCGN [14], and one had Churg-Strauss
syndrome (CSS), defined as systemic vasculitis associated with
asthma and eosinophilia [15]. Patients consisted of 15 women
and 13 men. The mean age at the time of the initial serum
sampling was 53 years (range 13 to 85).
Serum samples obtained at the time of diagnosis, before
initiation of treatment, were stored at —20°C until assayed.
Successive sera from 14 out of 28 patients were also drawn and
studied during a mean follow-up of 23 13 months (range 3 to
52).
Detection of ANCA by indirect immunofluorescence (hF)
ANCA determination by hF was perfomed according to the
recommendations of the First International ANCA Workshop
[16] on 1/16 diluted sera using ethanol-fixed neutrophils (PMN).
ELISA assays
ELISA Luxion plates (96-well; CML, Nemours, France)
were coated with 2 p,g/ml purified azurophilic granule enzymes
(myeloperoxydase from human sputum, Elastin Product Co,
Missouri, USA, and proteinase 3 purified as described in [17]) in
0.2 M borate buffer saline pH 8.2 (BBS) overnight at 4°C. Wells
were saturated with 1% gelatin in PBS for one hour at 37°C,
then sera to be tested were diluted 300-fold in 0.5% Tween 20
PBS (PBS-T) and incubated for one hour at 37°C. After washes
with PBS-T, alkaline phosphatase conjugated goat F(ab')2 frag-
ments specific for human y-, -or a-chain (Sigma) were diluted
1/1000 in PBS-T and added. Then plates were incubated for 90
minutes at 37°C and enzyme activity was revealed using Sigma
104 phosphatase substrate according to the manufacturer's
instructions. IgG anti-MPO ANCA were expressed in arbitrary
units defined by comparison with the European Study standard
serum (Bou.) containing by definition 1000 arbitary units (AU).
1gM and IgA anti-MPO antibody values were expressed in OD
units after substraction of the controls (mean value SD of
1gM and IgA anti-MPO antibodies present in 18 normal human
sera).
Apparent affinity constant (aK) determination
The apparent affinity constant (aK) was determined as de-
scribed [18—20] as the reciprocal value of MPO molar concen-
tration in the liquid phase resulting in 50% inhibition of ANCA
binding to MPO in the solid phase ELISA. Briefly, the serum
concentration required for competitive assay was first deter-
mined for each patient as the serum dilution giving about 70% of
the maximum binding in the standard MPO ELISA (Fig. IA).
The competitive binding assay was performed by first incubat-
ing, for two hours at 37°C, increasing amounts of MPO (up to 7
X iO M) in PBS-T with the adequate concentration of patient
anti-MPO antibodies determined as described above. The mix-
ture was then transferred to MPO-coated plates for the standard
ELISA procedure. The IgG anti-MPO binding was then ex-
pressed as percent of control binding determined in absence of
fluid phase MPO (Fig. IB).
To determine the anti-MPO 1gM aK, the same procedure was
MPO, pg/rn!
Fig. 1A. Determination of the patient's serum dilution giving about
70% at the maximum binding of ANCA in the standard IgG anti-MPO
ELISA. Sera a, c and d were initial sera from patients no. 1, 6 and 11,
respectively, and serum b was withdrawn from patient no. 14 during
follow-up. Sera a, b, c and d, respectively, contained 3000, 550, 167 and
20 arbitrary units of IgG anti-MPO. B. Inhibition profiles of IgG
anti-MPO ANCA. Inhibition of antibody binding to MPO in the solid
phase by increasing concentrations of fluid phase MPO (sera a-d were
tested at the dilution indicated by arrows on Fig. IA). The apparent
affinity constant (aK) was determined as the reciprocal value of MPO
molar concentration resulting in 50% inhibition of ANCA binding to
MPO in the fluid phase ELISA. aK was respectively 16, 0.l4, 60 and
0.l4 X l0 M1 for sera a, b, c and d.
performed on four selected sera containing high concentrations
of anti-MPO 1gM. The appropriate serum dilution and the
antibody binding values were determined using an anti-human s
chain (Sigma) conjugated with alkaline phosphatase.
Serum 1gM immunoabsorption procedure
Whole 1gM depletion by specific immunoabsorption was
performed on six selected sera containing high level 1gM
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Table 1. Clinical and immunological data of the 28 patients studied
Patient
no. Sex Age Disease
Organ
involvement
Renal funct
Crm AHD
ion
CHD
mv
RX
Lung
olvem
AIvH
ent
AST
Anti-MPO is
IgG 1gM
(AU) (OD)
otype
IgA
(OD)
Anti-MP
aK x iO
moliliter
0 IgG
max.inh
%
Anti-MPO 1gM
aK x
mol/liter
1 F 64 MPA KJ 180 — — — — — 3000 1036 — 16 92 12
2 F 41 WG KSNM 140 — — — — — 250 1367 — 0.l4 39 1.3
3 M 60 MPA KENT 200 — — — — — 30 674 — 0.6 72 ND
4 F 13 WG KLENTEy 180 — — + + — 125 1027 — 0.l4 0 ND
5 F 60 WG KLENTEyS 850 + - — - - 450 - - 90 95 ND
6 M 65 ChS KL 220 — — + — + 167 — — 60 95 ND
7 M 18 MPA KL - + + + - 1000 - - 55 99 ND
8 F 71 MPA KLS 270 — — + + — 334 66 — 3.8 87 ND
9 M 76 MPA KL 312 — — + + — 72 — — 25 86 ND
10 M 85 MPA KLENTEy 220 — — + — — 1150 249 — 2 80 ND
11 F 67 MPA KLENTEyS — + + + — 37 — — 0.14 7 25
12 M 59 RPGN K 850 + — — — — 167 101 — 8 71 ND
13 F 69 MPA KJEN 370 — — — — — 17 — —
0.14 0 ND
14 F 55 MPA KLJENTNG 150 — — + -F — 500 — — 0.6 56 ND
15 M 53 RPGN K — + — — — 124 792 — 0.7 79 ND
16 M 51 MPA KJ 250 — — — — — 182 1091 200 0.l4 19 ND
17 F 14 RPGN K — + — — — 84 — — 0.35 92 ND
18 M 52 MPA KL 180 — — — — — 83 1158 — 0.45 61 ND
19 M 58 MPA KJ 250 — — — — — 27 — — 1.7 88 ND
20 F 60 MPA KLENT 350 — — — — + 1000 — — 9 78 12
21 F 53 MPA KLENTJS 210 — — + + + 66 656 — 0.3 74 ND
22 F 53 MPA KJS — + — — — 300 — — 65 72 ND
23 M 47 WG KLENTS 180 — — + + — 100 — — 1.4 70 ND
24 M 78 WG KLENT 250 - - + - - 300 - - 200 90 ND
25 F 65 MPA KENTJ — + — — — 14 — — 0.14 24 ND
26 F 45 WG KLENTJS — + + — — 267 — — 0.4 70 ND
27 F 16 MPA KL — + — — — 14 586 — 0.l4 0 ND
28 M 24 MPA KLJM 100 — — — — — 280 — 200 0.14 19 ND
Abbreviations are: MPA, microscopic polyangitis; WG, Wegener granulomatosis; ChS, Churg-Strauss syndrome; RPON, rapidly progressive
glomerulonephritis; K, kidney; J, joint; S, skin; N, neurological; ENT; ear nose and throat; M, muscle; Ey, eyes; L, Lung; AHD, acute
hemodialysis; CHD, chronic hemodialysis; RX, radiological; AIvH, alveolar hemorrhage; AST, asthma; AU, arbitrary unit; OD, optical density;
aK, apparent affinity constant; max.inh, maximal inhibition; ND, not determined; +, present or positive; —, absent or negative.
anti-MPO antibodies. Anti-human 1gM and anti-human IgG
immunoadsorbents and control immunoadsorbent were pre-
pared respectively from 2 mg of affinity-purified goat anti-
human chain (Sigma), anti-human y chain (Atlantic Antibod-
ies, Stillwater, Minnesota, USA) and anti-human complement
protein C5 (Atlantic Antibodies) coupled to cyanogen bromide-
activated Sepharose 4B according to the manufacturer's in-
structions (Pharmacia). One ml of patient's sera diluted twen-
tyfold in PBS was incubated with an equal volume of anti-s,
anti-y and control Sepharose 4B by two hour rotation at room
temperature, followed by overnight rotation at 4°C. Untreated
and immunoadsorbed sera were tested for IgG and 1gM anti-
MPO ANCA and for apparent affinity of IgG anti-MPO ANCA.
These variables were expressed as a percentage of the preab-
sorption value.
Statistical methods
The unpaired Student's t-test was used to compare quantita-
tive parameters. The one factor ANOVA test was applied for
detecting correlations between the different qualitative param-
eters. The Wilcoxon signed rank test was also used when
indicated. A P value of <0.05 was considered significant.
Results
Clinical manifestations of vasculitis and isolype distribution
of MPO ANCA
Clinical features and laboratory findings in the 28 patients (at
the onset of their disease and before immunosuppressive ther-
apy was instituted) are presented in Table 1. The initial sera
were all positive by routine hF determination, with a perinu-
clear pattern, and contained IgG anti-MPO antibodies as as-
sessed by specific ELISA. None of them contained IgG anti-
PR3 [21]. In addition, we observed 1gM and IgA anti-MPO
ANCA, respectively, in 12 (43%) and 2 (7%) patients out of 28.
No relation was observed between isotype distribution and
disease pattern (number and type of organs involved, degree of
renal damage, and respiratory tract involvement). In particular,
no significant correlation was found between 1gM anti-MPO
ANCA and alveolar hemorrhage. In fact, 1gM anti-MPO ANCA
was found in 3 out of 12 patients having alveolar hemorrhage
and conversely in 9 out of 20 without this feature. Furthermore,
the two patients with low amounts of IgA anti-MPO ANCA did
not differ clinically from the others.
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Level and affinity of IgG anti-MPO ANCA in relation with
disease pattern at presentation
The level of IgG anti-MPO ANCA was determined after
serum dilution and by comparison with that obtained after
dilution of a standard serum (containing 1000 AU/mi). High IgG
anti-MPO ANCA titers were usually observed at the onset of
the disease (Table 1). However, no relation was observed
between IgG anti-MPO ANCA level and disease pattern (num-
ber of organs involved, presence of renal failure or alveolar
hemorrhage). For example, renal failure, defined by plasma
creatinine level above 200 molIiiterat the onset of the disease,
was not correlated with a tendency towards higher affinity (aK
= 24.9 48 vs. 2.7 5.8, P = 0.414) and higher level of IgG
anti-MPO ANCA (276 + 347 AU vs. 619 + 1059 AU, P = 0.19)
by using the Wilcoxon signed rank test.
Affinity of IgG anti-MPO ANCA in relation with serum level
and the presence of 1gM anti-MPO ANCA
The comparison between level and affinity of IgG anti-MPO
ANCA in initial sera is presented in Figure 2. No correlation
was found between these two variables. With regard to the
presence of a high level of 1gM anti-MPO ANCA, defined by an
ELISA signal higher than 0.5 OD unit, we observed that 8 out
15 sera containing low affinity IgG anti-MPO ANCA (aK < 1)
also contained 1gM anti- MPO ANCA (Fig. 2). Conversely, only
one out of 13 sera containing high affinity IgG anti-MPO ANCA
(aK> 1) also contained 1gM anti-MPO ANCA. Although clear,
this difference did not reach statistical significance since the aK
(mean + SD) was respectively 2.7 4.8 in the group of sera (N
= 9) containing high levels of 1gM anti-MPO ANCA and 32 53
in the group (N = 19) containing low levels or no 1gM anti-MPO
ANCA, (P = 0.07).
Affinity and level of IgG and 1gM anti-MPO ANCA during
follow-up
Fourteen patients out of 28 were followed up for a mean of 23
13 months (range 3 to 52). During follow-up four patients out
of 14 had relapses, three with MPA and one with NCGN. Three
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of the four relapsing patients presented with deterioration of
renal function and concurrent alveolar hemorrhage.
Both level and affinity of IgG anti-MPO ANCA were de-
creased after two to six months of immunosuppressive therapy
as shown in Figure 3. The apparent affinity constant, initially
high in nine out of 14 sera, decreased rapidly to undetectable
levels in the majority of patients (Fig. 3). The aK remained low
in 12 out of 14 patients even when relapses occurred in four
cases (patients no. 8, Fig. 4B; no. 10, Fig. 4C; no. 12, Fig. 4A
and no. 28, not shown). This sharp and stable fall in aK
contrasted with the slower decrease of anti-MPO IgG level
which remained high (>30 AU) in 6 out of 14 patients at two to
six months.
Prolonged follow-up of four informative patients is presented
in Figure 4. In one transplanted patient (no. 22 ,Fig. 4D) both
the level and the affinity of IgG anti-MPO ANCA remained high
despite clinical remission of the vasculitis. This was also
observed in one patient presenting with Churg-Strauss syn-
drome (no. 6, not shown here). In the two patients where
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relapse was associated with an increased IgG anti-MPO ANCA
level, prior elevation of 1gM anti-MPO ANCA was observed, as
shown in Figure 4A (patient no. 12) and 4B (patient no. 8).
Absence of effect of 1gM depletion on lgG anti-MPO ANCA
level and affinity determination
Six patients' sera containing 1gM anti-MPO ANCA were
studied at presentation (patients no. 1 and 2) or during evolution
(patients no. 8, 21 and no. 12 at 16 months and 21 months). The
sera were 1gM-depleted by specific immunoadsorption on an
anti-human 1gM column. This procedure removed more than
75% of 1gM as measured 1gM anti-MPO ANCA ELISA. The
1gM-depleted sera retained an unmodified level and affinity of
IgG anti-MPO ANCA as compared with the non-depleted sera
or with the sera incubated on control Sepharose 4B immunoad-
sorbent. Conversely, IgG depletion removed more than 65% of
IgG anti-MPO ANCA without affecting the 1gM anti-MPO
ANCA level.
Discussion
ANCA titers and disease activity have generally been ob-
served to be correlated [4-6, 22]. However, since in a substan-
tial minority of patients ANCA titers do not follow disease
activity, titers should not be used as the sole criterion for
initiating or changing therapy. Given these limitations, we
investigated whether the determination of isotype together with
affinity of anti-MPO ANCA might be of clinical interest. To do
so, we used an ELISA specific for MPO and determined the
affinity of IgG anti-MPO by fluid phase inhibition with MPO
[18—20]. The ability of this method to measure the aK of a
heterogeneous mixture of antibodies without prior fractionation
is based on the fact that, although both high- and low-affinity
antibody subpopulations are able to bind the antigen at a given
concentration, aK measurement of lower affinity antibodies is
not influenced by the presence of higher affinity subpopulations
[23]. Although validated in different antigen antibody systems,
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the methodology used here is indirect; the only accurate deter-
mination of antibody affinity would rely on direct measure of
affinity-purified antibodies which cannot be applied to large
number of samples. The possible artifactual interaction of
immune complexes in ELISA is unlikely since no binding was
observed on saturated uncoated wells. We were also concerned
with the possible binding of immune complexes to MPO, and as
well as several other authors [16, 21], we used limited amounts
of antibodies and excess fluid phase MPO concentration to
minimize eventual remaining free antibody sites in the pre-
formed complexes. Furthermore, we have never observed an
increased binding after incubation with fluid phase MPO.
The question of the clinical relevance of the isotype distribu-
tion of ANCA has been only partly answered. Indeed, the
presence of 1gM ANCA together with IgG was found to be
associated with pulmonary hemorrhage [11]; conversely, this
clinical manifestation was not found in patients with IgG but no
Fig. 4. Continued.
1gM ANCA [121. On the contrary, we observed that 1gMANCA
was not closely linked to pulmonary hemorrhage, since it
occurred in the absence of 1gM ANCA in nine patients.
Furthermore, 1gM ANCA were not correlated to any particular
clinical setting, but frequently occurred early in the course or
during relapses of the disease, often before detection of IgG
ANCA. Our results would favor the hypothesis that 1gM ANCA
may not have a pathogenetic role and more probably reflect the
early phase of the autoimmune response. Thus, 1gM ANCA
may artificially appear more frequent wben the revealing clini-
cal manifestation is clearly visible and lead to ANCA determi-
nation during the early phase of the vasculitis. Altogether our
data show that 1gM ANCA has no clinical relevance in spite of
previous claims [II, 12J. IgA anti-MPO ANCA were uncommon
(2 patients out of 28) and not associated with a particular
symptom, as we have already shown in another series of
patients with PR3- and MPO-ANCA associated vasculitis [241.
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We observed that the level and affinity of IgG anti-MPO
ANCA were not correlated and that the presence of large
amounts of 1gM anti-MPO ANCA was associated with low
affinity IgG anti-MPO and was observed in the early phase of
relapses. This is made coherent by the fact that a switch from
1gM to IgG autoantibody production plays a role in the emer-
gence of many autoimmun diseases [25]. This might also be
true in ANCA vasculitic patients since we have never observed
1gM anti-MPO without IgG in such a patient.
The most interesting observation in our study is the decrease
of IgG anti-MPO affinity after treatment. During follow-up, the
high affinity IgG anti-MPO remained suppressed for prolonged
periods of time and unexpectedly did not reappear during
relapses, as shown by the predominant recurrence of low-
affinity IgG anti-MPO. Several hypotheses might be considered
to explain this observation.
First, the decrease in affinity of IgG ANCA may reflect a
variation in IgG subclass distribution with time. It has been
established that ANCA belong predominantly to the IgGi and
IgG4 subclass [26—29]. Brouwer et al found no difference in
ANCA subclass distribution and levels between patients at
initial presentation and in relapse and also observed that the
subclass distribution was not correlated with particular clinical
manifestations, although there was a tendency towards higher
levels of IgG3 class MPO ANCA in patients with renal involv-
ment [26]. Importantly Jayne, Weetman and Lockwood [28]
found that the level of IgG3 anti-MPO was lower in 12 follow-up
sera compared to the initial sera, and more recently Segelmark
and Wieslander [291 reported in a cross-sectional study that sera
containing ANCA of one single subclass were preferentially
seen in patients in remission. Thus, the role of ANCA subclass
variation in the disappearance of high affinity ANCA during
evolution remain undetermined.
Second, the interactions of the variable region of IgG au-
toantibodies with those of 1gM in the serum could be a means of
regulating the autoreactive IgG [30, 31]. This has been shown in
normal mice, where the binding of IgG autoantibodies to self
antigens was inhibited by normal polyclonal 1gM [32]. Recently,
regulatory F(ab')2-reactive 1gM which inhibited some IgG au-
toantibody activities have also been described in patients with
ANCA vasculitis [33]. In this work, the authors suggested that
remission was associated with the generation of 1gM anti-
idiotypes inhibiting IgG ANCA rather than the suppression of
ANCA producing clones. On the contrary, in our hands, serum
1gM immunoadsorption did not modify the amount or affinity of
IgG anti-MPO ANCA, as determined by ELISA. We would
therefore favor the hypothesis of a decrease in synthesis rather
that an inhibition by anti-idiotype antibodies to explain the
decrease in IgG anti-MPO and the disappearance of high affinity
IgG autoantibodies during follow-up. The absence of detectable
1gM interacting with IgG anti-MPO may also be important in the
appearance of ANCA, since it has already been shown that 1gM
fails to inhibit IgG autoantibodies in some pathological situa-
tions in mice [30].
Third, ANCA antigen expression may vary with neutrophil
activation and could be responsible for the variations in both
level and affinity of IgG anti-MPO. The most convincing evi-
dence that B cells producing autoantibodies are selected by
antigen is the existence of somatic mutations [25] and high
affinity in the autoantibody response [34]. Additional support
for the antigen-driven hypothesis comes from the occurrence of
autoantibody responses to different antigens present in intracel-
lular organelles such as nucleosomes for antinuclear antibodies
[25] or primary granules for ANCA. The decrease in IgG
anti-MPO ANCA level as well as affinity may be linked to the
disappearance of the antigen source, that is the expression of
lysosomal enzymes secondary to neutrophil activation as it is
observed in the obese chicken strain where removal of the
thyroid at birth completely suppresses the development of
thyroid autoantibodies and once thyroid autoimmunity has been
established, removal of the thyroid leads to a decline in thyroid
autoantibodies [25].
In conclusion, our work demonstrates that determination of
level, isotype distribution and affinity of anti-MPO ANCA is not
of clinical importance. However, two interesting observations
emerge; namely an 1gM to IgG switch of anti-MPO antibodies
during relapses, and disappearance of high affinity IgG anti-
MPO clones after therapy despite reappearance of low affinity
IgG anti-MPO antibodies.
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